Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.41 Analyst target: $29.83 Upside: 774.78%
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.